Central Nervous System Diseases clinical trials at University of California Health
4 in progress, 2 open to eligible people
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
open to eligible people ages 1 month to 6 years
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
at UCSF
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
open to eligible people ages 1 month to 6 years
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
at UCSF
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Sorry, in progress, not accepting new patients
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate video scale assessments.
at UC Irvine
Human Epilepsy Project 2: Resistant Focal Seizures Study
Sorry, in progress, not accepting new patients
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
at UCSF
Our lead scientists for Central Nervous System Diseases research studies include Daniel Lowenstein, MD.
Last updated: